| П | <u>:</u> | | |
|---|----------|---|--|
| Г | П | ш | |

Reset



| WMDA TC Evaluation Reviewer Checklist | | | | | | | |
|---------------------------------------|---------------------------------------|-----------------|----------|--|--|--|--|
| Document type | Form | Approved by | | | | | |
| Document reference | WMDA TC Evaluation Reviewer Checklist | Approval date | 20230713 | | | | |
| Version | 1.0 | Approval status | | | | | |
| Pillar / Scope | P2 | Status | Public | | | | |

| WI | MDA Office | | | | | |
|-----|---|----------------------------------|-----|----|-----|----------|
| App | olicant Transplant Center Name: | | | | | |
| Reg | istry Name (if applicable): | | | | | |
| Rev | iewer Name: | | | | | |
| Rev | iew Date: | | | | | |
| CRI | TERIA ASSESSMENT (indicate if o | riteria has been met) | Yes | No | N/A | Comments |
| Ger | neral Information | | | | | |
| 1. | Mailing address | | | | | |
| Fac | cility Description | | Yes | No | N/A | |
| 2. | Year HSCT program began perfor Information Only | ming allogeneic transplants. | | | | |
| 3. | Adults and/or pediatric patients. <i>Information Only</i> | | | | | |
| 4. | Indicate number of beds for each Information Only | n adult and pediatrics. | | | | |
| 5. | Inpatient rooms have defines pra airborne contamination. <i>Must be yes</i> | actices to minimize the risk of | | | | |
| 6. | All patient treatment areas (both minimize the risk of infection. | inpatient and outpatient/clinic) | | | | |
| | Must be yes | | | | | 1 |



| WMDA TC Evaluation Reviewer Checklist | | | | | | | | |
|---------------------------------------|---------------------------------------|-----------------|----------|--|--|--|--|--|
| Document type | Form | Approved by | | | | | | |
| Document reference | WMDA TC Evaluation Reviewer Checklist | Approval date | 20230713 | | | | | |
| Version | 1.0 | Approval status | | | | | | |
| Pillar / Scope | P2 | Status | Public | | | | | |

| 7 | Registration, license, or accreditation certificate(s) by national government (if applicable) and/or other agency relevant to HSCT. Certificate(s) must be attached and current if applicable | | | | |
|-----------|--|-----|----|-----|--|
| 8. | List the number of patients who received transplants in each of the last two years by stem cell source. Information only | | | | |
| 9. 10. | Survival rate for patients (both adult and pediatric as applicable) should be >50% at one year after allogeneic transplantation. Discuss with WMDA clinical reviewer or registry physician if fewer than 5 allo transplants and/or survival rate is less than 50% | | | | |
| Pers | sonnel / Transplant Team | Yes | No | N/A | |
| 11. | Medical Director has at least two years of allogeneic HSCT experience, including one year of unrelated donor transplantation experience, in his/her career. Contact details are indicated. Must be yes AND copy of CV must be attached | | | | |
| | At least one additional physician has a minimum of one year of allogeneic HSCT experience. Must be yes | | | | |
| 12. | Physician coverage 24 hours per day, seven days per week. Must be yes | | | | |
| 13. | Transplant team includes nurses with training and experience in the care of transplant patients. Must be yes | | | | |



| WMDA TC Evaluation Reviewer Checklist | | | | | | | |
|---------------------------------------|---------------------------------------|-----------------|----------|--|--|--|--|
| Document type | Form | | | | | | |
| Document reference | WMDA TC Evaluation Reviewer Checklist | Approval date | 20230713 | | | | |
| Version | 1.0 | Approval status | | | | | |
| Pillar / Scope | P2 | Status | Public | | | | |

| 14. | Coordinator or other key personnel proficient in English and available to provide daily and emergency communication and logistical coverage. Must be yes | | | | |
|-----|---|-----|----|-----|--|
| | Designated backup coordinator name and contact information. <i>Information Only</i> | | | | |
| 15. | Emergency/afterhours contact information provided. Must be yes | | | | |
| Sı | ipport Services | Yes | No | N/A | |
| 16. | Support from an HLA laboratory that is accredited by an established accrediting agency. Lab accreditation agency should be indicated | | | | |
| 17. | Support from an IDM (Infectious Disease Markers) laboratory that is accredited by a national authority. Lab accreditation agency should be indicated | | | | |
| 18. | Support from an accredited stem cell processing laboratory that has capability to perform all 3 designated functions. Lab accreditation agency should be indicated; Must be yes to all 3 laboratory functions | | | | |
| Po | licies and Administration | Yes | No | N/A | |
| 19. | Willing to comply with designated patient outcome reporting policies to established outcomes registry. Should be yes | | | | |
| 20. | Adheres to applicable WMDA Standards. Must be yes | | | | |



| WMDA TC Evaluation Reviewer Checklist | | | | | | | |
|---------------------------------------|---------------------------------------|-----------------|----------|--|--|--|--|
| Document type | Form | | | | | | |
| Document reference | WMDA TC Evaluation Reviewer Checklist | Approval date | 20230713 | | | | |
| Version | 1.0 | Approval status | | | | | |
| Pillar / Scope | P2 | Status | Public | | | | |

| 21. | Policy for research studies in place. Should be yes |
|-----|---|
| 22. | Defined criteria outlining diagnostic categories acceptable for unrelated HSCT. Must be yes AND policy attached or identification of other criteria used (e.g., EBMT, ASBMT, etc) |
| 23. | Defined criteria for acceptable level of HLA matching between patient and donor. Must be yes AND policy/document attached |
| 24. | Policy for reporting serious adverse events. Must be yes |
| 25. | Policy for protecting donor and patient confidentiality. Must be yes |
| 26. | General and professional liability insurance. Should be yes |
| 27. | Consent form that includes information about the international donor search procedure as well as consent for the required transfer of personal and medical data is attached. Must be yes |



WMDA TC Evaluation Reviewer Checklist Document type Form Approved by Document reference WMDA TC Evaluation Reviewer Checklist Approval date 20230713 Version 1.0 Approval status Pillar / Scope P2 Status Public

| Conclusions | | | | | | | | | | |
|---|-----------------|-----------|-----------------------------|------------|--|--|--|--|--|--|
| Recommendation | Approve | Deny Requ | uest additional information | | | | | | | |
| Additional information requested (specify): | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Additional comments: | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Reviewer Name: | Reviewer title: | | Date: | Signature: | | | | | | |